Novavax Inc. closed 69.07% below its 52-week high of $23.86, which the company reached on June 6th.

The company has started to add bearish views on Wall Street as the healthcare giant's business practices draw public scrutiny, risking its prospects, worsened by its recent leadership change. Bank of ...

Moderna (MRNA), and Novavax (NVAX) agree as the FDA advisors recommend targeting JN.1 strain for updated COVID vaccines this ...

Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after BioMarin BMRN agreed to ...

This was the stock's second consecutive day of losses.

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

The approval marks a significant milestone for Novavax Inc. (NASDAQ:NVAX), aligning with the changing regulatory landscape ...

Shares of vaccine makers saw an uptick in the latest trading session, with Moderna Inc (BMV:MRNA). (NASDAQ:MRNA) leading the ...

The member states of the World Health Organization (WHO) on Tuesday adopted a landmark agreement to promote the timely and ...

GAITHERSBURG, MD, USA I May 19, 2025 I Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the ...